Drug Profile
Melatonin controlled-release - Neurim Pharmaceuticals
Alternative Names: Circadin; KI 1001 - Kuhnil; KI1001; Melatonin extended-release; Melatonin prolonged-release; Melatonin sustained-release; Orlogin; Paediatric Prolonged-Release Melatonin; PedPRM; Rx PedPRM; SlenytoLatest Information Update: 13 Nov 2021
Price :
$50
*
At a glance
- Originator Neurim Pharmaceuticals
- Developer Kuhnil Pharmaceutical Company; Neurim Pharmaceuticals; Sigma Pharmaceuticals
- Class Anti-inflammatories; Chemoprotectants; Hormones; Radioprotectives; Sleep disorder therapies; Tryptamines
- Mechanism of Action Antioxidants; Melatonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Insomnia
- Phase III Sleep disorders
- Discontinued Drug-induced dyskinesia
Most Recent Events
- 12 Mar 2021 Neurim Pharmaceuticals withdraws a phase III trial in Insomnia (NCT04233502) (PO)
- 22 Jan 2020 Neurim Pharmaceuticals plans a phase III trial for Insomnia in September 2020 (NCT04233502) (PO)
- 05 Nov 2018 Registered for Insomnia (In adolescents, In children) in Iceland, Liechtenstein, Norway, European Union (PO)